Skip to content

canopusrecord engine body

field
frontiers
loop
body
docs

vela-science/vela

frontier

pediatric-hgg

findings

vf_f6fd98935260314b

resultsread-only vieweressays

Search Canopus

Jump to a section, signal, campaign, document, primitive, work path, frontier, record index, atlas, constellation, agent, capability, or full-state search.

frontiers / frontier

Pediatric high-grade glioma: distinct biology, distinct trials

CC-BY-4.0vfr_10815170943966df

id: vfr_10815170943966df
license: CC-BY-4.0
findings: 115
accepted core: 0
contested: 0

115

findings

76

links

113

sources

115

evidence

0

contested

0.82

avg conf

recordoverview state sources proofenginereviewbodygraph

Finding bundle

ONC201/GsONC201 treatment in 28 H3K27M-mutant DIPG patients achieved median overall survival of 18 months; reirradiation-treated patients showed OS of 22 months versus 12 months without reirradiation, suggesting synergy between ONC201 and radiation

3inferred

id: vf_f6fd98935260314b
frontier: Pediatric high-grade glioma: distinct biology, distinct trials
version: 1
confidence: 0.85

record state

frontier-owned

Review status

This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.

unreviewed

finding statement

finding type

therapeutic

No entity list is declared.

evidence

source-bound

1 atoms

theoretical · manual state transition

proof impact

packet context

1 events

1 reviewable changes and 0 evaluation records are attached to this finding id.

Evidence and conditions

method

manual state transition

evidence type

theoretical

conditions

species_unverified
species_verified
text: Retrospective cohort analysis of GsONC201-treated H3K27M DIPG patients

Provenance

source title

ONC201 clinical efficacy in H3K27M-mutant gliomas (Cancer Discovery)

authors

reviewer:will-blair

Source records

1

source record

ONC201 clinical efficacy in H3K27M-mutant gliomas (Cancer Discovery)

vs_548c1751a8b99905

title:ONC201 clinical efficacy in H3K27M-mutant gliomas (Cancer Discovery)

2021manual_curation

inspect source →

Evidence atoms

1

vea_d1de45890179fe43theoretical · unknown
ONC201/GsONC201 treatment in 28 H3K27M-mutant DIPG patients achieved median overall survival of 18 months; reirradiation-treated patients showed OS of 22 months versus 12 months without reirradiation, suggesting synergy between ONC201 and radiation
vs_548c1751a8b99905 · manual_curation

Typed links

3

outgoing

No outgoing links.

incoming

Patients with H3K27M-mutant DMG demonstrate median overall survival of 10.1-14.4 months from diagnosis, with 5-year survival <2%, compared to 54-60 Gy focal radiotherapy as the only standard-of-care intervention showing modest survival benefit
supports · vf_730821613735146b
MGMT promoter unmethylation and elevated MGMT expression confer resistance to temozolomide in H3K27M gliomas; three of four patient-derived DMG cell lines showed MGMT-driven TMZ resistance independent of MGMT methylation status
contradicts · vf_7bd0c5cb3f52944d
Targeting DNA repair (homologous recombination blockers) combined with PI3K/EGFR inhibitors and radiotherapy induces synthetic lethality in patient-derived DIPG models, suggesting multi-pathway DNA-damage sensitization overcomes radiotherapy resistance
supports · vf_2391a24d566733fb

Review, event, and evaluation records

2

events

vev_e6172f3a7315fec1finding.asserted
Manual finding added to frontier state
reviewer:will-blair · 2026-05-29

reviewable changes

vpr_336630fcf762ef9dfinding.add
Manual finding added to frontier state
applied · reviewer:will-blair · 2026-05-29

evaluations

No evaluation record targets this finding id.